LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry

• Published in: Cardiovascular drugs and therapy 2022-04, Vol.36 (2), p.301-308
• Main Authors: Climent, Elisenda, Bea, Ana M., Benaiges, David, Brea-Hernando, Ángel, Pintó, Xavier, Suárez-Tembra, Manuel, Perea, Verónica, Plana, Núria, Blanco-Vaca, Francisco, Pedro-Botet, Juan
• Format: Article
• Language: English
• Subjects: Anticholesteremic Agents - adverse effects; Arteriosclerosis; Arteriosclerosis - drug therapy; Body mass; Body mass index; Body size; Cardiology; Chemotherapy; Cholesterol; Cholesterol, LDL; Combined treatment; Drug therapy; Drug Therapy, Combination; Dyslipidemia; Dyslipidemias - diagnosis; Dyslipidemias - drug therapy; Ezetimibe - adverse effects; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Hypercholesterolemia; Hypercholesterolemia - diagnosis; Hypercholesterolemia - drug therapy; Lipids; Low density lipoprotein; Male; Males; Medicine; Medicine & Public Health; Metabolic disorders; Original Article; Reduction; Registries; Rosuvastatin Calcium - adverse effects; Sex; Simvastatin; Simvastatin - adverse effects; Statins; Variability
• ISSN: 0920-3206; 1573-7241
• DOI: 10.1007/s10557-020-07137-z

Purpose Low-density lipoprotein (LDL) cholesterol reduction by statin therapy is dose-dependent, varies among different statins, and has wide inter-individual variability. The present study aimed to compare mean LDL cholesterol reduction and its variability achieved with different doses of the three statins most frequently used in monotherapy or combined with ezetimibe in a real clinical setting. Methods Of 5620 cases with primary hypercholesterolemia on the Spanish Arteriosclerosis Society Registry, 1004 with non-familial hypercholesterolemia and complete information on drug therapy and lipid profile were included. Results The lowest mean percentage LDL cholesterol reduction was observed with simvastatin 10 mg (32.5 ± 18.5%), while the highest mean percentage LDL reduction was obtained with rosuvastatin 40 mg (58.7 ± 18.8%). As to combined treatment, the lowest and highest mean percentage LDL cholesterol reductions were obtained with simvastatin 10 mg combined with ezetimibe (50.6 ± 24.6%) and rosuvastatin 40 mg combined with ezetimibe (71.6 ± 11.1%), respectively. Factors associated with a suboptimal response were male sex, lower age, body mass index, and baseline LDL cholesterol levels. Combined treatment was associated with less variability in LDL cholesterol reduction (OR 0.603, p